哌罗匹隆与喹硫平治疗首发精神分裂症临床效果对照研究

A Comparative Study of Piperapril and Quetiapine in the Treatment of First-episode Schizophrenia Patients

目的对比哌罗匹隆与喹硫平治疗首发精神分裂症的临床疗效及安全性。方法回顾性分析2015年1月—2016年5月在我院住院治疗的首发精神分裂症患者102例的临床资料,按照治疗方法分为两组,对照组和观察组各51例,观察组用哌罗匹隆治疗,对照组用喹硫平治疗,两组连续治疗8周后比较临床疗效及不良反应情况。结果观察组有效率(76.47%)与对照组(70.59%)比较,差异无统计学意义(P>0.05)。观察组不良反应发生率(56.86%)与对照组(60.78%)比较,差异无统计学意义(P>0.05),观察组内分泌改变、体质量增加发生率与对照组比较更低,两组差异有统计学意义(P<0.05)。结论在治疗首发精神分裂症方面,哌罗匹隆与喹硫平的临床疗效相近,均有较高的安全性,但是哌罗匹隆在内分泌及体质量改变方面更低。

Objective To evaluate the clinical efficacy and safety of piperapril and quetiapine in the treatment of first-episode schizophrenia. Methods The clinical data of 102 patients with first episode schizophrenia who were hospitalized in our hospital from January 2015 to May 2016 were analyzed retrospectively. They were divided into two groups according to the treatment methods, there were 51 cases in the control group and the observation group. The observation group treated with piperapril, the control group treated with quetiapine, the clinical efficacy and adverse reactions of two groups after 8 weeks of continuous treatment were compared. Results The effective rate was 76.47% in the observation group and 70.59% in the control group, the difference was not statistically significant(P > 0.05). The incidence of adverse reactions in the observation group was 56.86% and 60.78% in the control group, the difference was not statistically significant(P > 0.05). The incidence of endocrine changes and the increase of body weight in the observation group were lower than those in the control group, the difference was statistically significant(P < 0.05). Conclusion The efficacy of piperapril and quetiapine in the treatment of first-episode schizophrenia is similar, but piraulone is lower in endocrine and body mass changes.